Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

The stock market heads into the final week of June with an eye on Tesla, Novo Nordisk, defense stocks and weekly jobless ...

Hims & Hers Health, Inc. sees 38% YoY subscriber growth, driven by 70% choosing personalized treatments. Click for my updated ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

According to Benzinga Pro, Novo Nordisk's peer group average for short interest as a percentage of float is 4.03%, which ...

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the ...

Wednesday marked a losing session on Wall Street, with the S&P 500 snapping its three-day win streak, as did the Nasdaq ...